Leerink Maintains Outperform Rating as Bristol Myers (BMY) Expands ADEPT-2 Enrollment

Bristol-Myers Squibb Company (NYSE:BMY) is included among the 14 Best US Stocks to Buy for Long Term. Leerink Maintains Outperform Rating as Bristol Myers (BMY) Expands ADEPT-2 Enrollment On December 4, Leerink analyst David Risinger maintained an Outperform rating on Bristol-Myers Squibb Company (NYSE:BMY). The analyst highlighted that the company plans to enroll more patients in the ADEPT-2 study and sees this as a positive development. He noted that the Data Monitoring Committee also suggested expandi ...